← Return to Aromatase Inhibitors: Did you decide to go on them or not?
DiscussionAromatase Inhibitors: Did you decide to go on them or not?
Breast Cancer | Last Active: May 12, 2023 | Replies (1190)Comment receiving replies
Replies to "I am trying to understand. Oncotype does two things: assesses risk of distant recurrence, and benefit..."
I can't speak to how people would likely evaluate the OncotypeDX score but it helped me skip "clean-up" radiation because it was too small a risk reduction versus possible side effects. Someone else might say that she wants every conceivable weapon available tossed at the recurrence risk, even just in that one tiny area. My breast surgeon, on the basis of pre- and post-surgical biopsies assumed that radiation wouldn't even be recommended. And the radiologist did offer it as an option, but not an insistent recommendation.